Sites and severity of infection for patients with SLE in each group
| SILD IV-CYC (N=506) | HD IV-CYC (N=256) | P value | |||
| n | % | n | % | ||
| Infection | 66 | 13.04 | 57 | 22.27 | 0.001* |
| Infection sites | |||||
| Respiratory tract | 52 | 10.28 | 39 | 15.23 | 0.046* |
| Skin and soft tissue | 9 | 1.78 | 11 | 4.30 | 0.040* |
| Urinary tract | 5 | 0.99 | 3 | 1.17 | 1.000 |
| Gastrointestinal tract | 3 | 0.59 | 5 | 1.95 | 0.173 |
| Other (haematologic, central nervous, etc) | 4 | 0.79 | 2 | 0.78 | 1.000 |
| Multiple sites | 11 | 2.17 | 6 | 2.34 | 0.881 |
| Severity of infection | |||||
| Mild infection | 30 | 5.93 | 24 | 9.38 | 0.080 |
| Moderate infection | 24 | 4.74 | 22 | 8.59 | 0.035∗ |
| Severe infection | 12 | 2.37 | 11 | 4.30 | 0.142 |
*P value <0.05. All p values less than 0.05 which is significant are in bold.
HD IV-CYC, high-dose intravenous cyclophosphamide; SILD IV-CYC, short-interval and lower-dose intravenous cyclophosphamide.